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Abstract
Background:  The aberrant release of the neurotransmitters, glutamate and calcitonin-gene
related peptide (CGRP), from trigeminal neurons has been implicated in migraine. The voltage-
gated P/Q-type calcium channel has a critical role in controlling neurotransmitter release and has
been linked to Familial Hemiplegic Migraine. Therefore, we examined the importance of voltage-
dependent calcium channels in controlling release of glutamate and CGRP from trigeminal ganglion
neurons isolated from male and female rats and grown in culture. Serotonergic pathways are likely
involved in migraine, as triptans, a class of 5-HT1 receptor agonists, are effective in the treatment
of migraine and their effectiveness may be due to inhibiting neurotransmitter release from
trigeminal neurons. We also studied the effect of serotonin receptor activation on release of
glutamate and CGRP from trigeminal neurons grown in culture.
Results: P/Q-, N- and L-type channels each mediate a significant fraction of potassium-stimulated
release of glutamate and CGRP. We determined that 5-HT significantly inhibits potassium-
stimulated release of both glutamate and CGRP. Serotonergic inhibition of both CGRP and
glutamate release can be blocked by pertussis toxin and NAS-181, a 5-HT1B/1D antagonist.
Stimulated release of CGRP is unaffected by Y-25130, a 5-HT3 antagonist and SB 200646, a 5-HT2B/
2C antagonist.
Conclusion: These data suggest that release of both glutamate and CGRP from trigeminal neurons
is controlled by calcium channels and modulated by 5-HT signaling in a pertussis-toxin dependent
manner and probably via 5-HT1 receptor signaling. This is the first characterization of glutamate
release from trigeminal neurons grown in culture.
Background
Several lines of evidence indicate that both glutamate and
CGRP are important neurotransmitters in migraine. For
example, clinical studies indicate that CGRP is elevated in
plasma or platelets during migraine episodes [1] (how-
ever, see Tvedskov et al., 2005 [2]), presumably due to
activation of the trigeminovascular system. CGRP antago-
nists are being tested with some success as therapeutic
agents for acute migraine [3,4]. In a manner analogous to
CGRP, most studies indicate that glutamate is elevated in
the cerebrospinal fluid, plasma and/or platelets of
migraine sufferers [5-7]. Likewise, a novel AMPA/GluR5
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antagonist has recently been shown to be efficacious in
migraine [8]. Understanding the mechanisms which con-
trol the release of these two neurotransmitters may help in
the treatment of migraine as well as other painful diseases
associated with the trigeminal nerve including cluster
headache.
The regulated release of neurotransmitters, such as gluta-
mate and CGRP, is controlled by voltage-dependent cal-
cium channels, including P/Q- type channels. Missense
mutations in the P/Q-type channel have been identified
in Familial Hemiplegic Migraine (FHM), a type of
migraine with severe aura symptoms. The FHM mutation
(R192Q) has gain-of-function effects in cell lines (for
review, see Pietrobon, 2003 [9]) and results in increased
activity and excess release of neurotransmitter in a knock-
in mouse [10]. Functional studies to characterize the nor-
mal role of the P/Q-type channel in trigeminal ganglion
neurons may help in further understanding the patho-
physiology of migraine.
Currently, the most widely used specific acute anti-
migraine treatments are a class of 5-HT1B/1D receptor ago-
nists, the triptans, and clinical studies have demonstrated
that CGRP levels return to basal after sumatriptan and in
a similar time frame as headache relief [11]. Their mecha-
nism of action is not completely understood, but one
hypothesis suggests that triptans inhibit neurotransmitter
release from trigeminal neurons and subsequently attenu-
ate vasodilation, neurogenic inflammation and central
sensitization. As both glutamate and CGRP are co-local-
ized with 5-HT1B, 5-HT1D  and/or 5-HT1F  receptors in
trigeminal neurons [12,13] it was suggested that the
release of glutamate may be regulated in a similar manner
by 5-HT1 receptor activation. Pre-clinical studies have pro-
vided indirect evidence that triptans can inhibit the
release of glutamate or attenuate the action's of glutamate
in spinal cord slices presumably by a pre-synaptic mecha-
nism [14,15]. However, previous studies have not directly
examined the regulation of glutamate release by calcium
channels and 5-HT signaling in trigeminal neurons grown
in culture. Conducting our experiments on cells grown in
culture allows the delivery of drugs at known concentra-
tions and without the presence of additional modulatory
pathways. Our goals in these studies are two-fold: 1) to
characterize the roles of the P/Q-, N- and L-type calcium
channels in release of glutamate and CGRP from trigemi-
nal neurons grown in culture and 2) to examine the effects
of 5-HT receptor activation on release of glutamate and
CGRP.
Results
Role of calcium channels in release of glutamate and 
CGRP from trigeminal neurons
We examined the role of voltage-dependent calcium chan-
nels in release of glutamate and CGRP from trigeminal
neurons isolated from male rats or female rats grown in
culture. Several measures were used to ensure that compa-
rable numbers of viable cells were present in all wells
within a dish. Cells in representative wells were counted
immediately before the release experiment and trypan
blue exclusion was used to assess the viability of cells
before and after the release experiment. Cultures con-
tained 1800–2500 viable cells/well from male or female
rats at the time the release studies were performed. In
addition, the average basal releases of neurotransmitter
from each treatment group (in the absence of drugs) in an
experiment were within 30% of each other. The cells
exhibited robust KCl-stimulated neurotransmitter release
at least four-fold over the basal levels. Post-treatment
basal release (in the absence of drugs) was measured in all
CGRP assays and some glutamate assays and was not
more than 50% higher than initial basal levels indicating
that the release assay did not damage the cells or induce
cell lysis (data not shown). These observations when
taken together indicate that similar numbers of viable
cells were present in all wells within an experiment. We
also assessed the between experiment variability. For
example, the basal CGRP values for 32 independent
experiments from male rats averaged 15 ± 1.3 fmol/well/
10 min and ranged from 5 – 40 fmol/well/10 min. In
these 32 experiments the values for stimulated CGRP
release averaged 115 ± 4.5 fmol/well/10 min and ranged
from 80 – 175 fmol/well/10 min. The values for basal and
stimulated release of CGRP did not differ significantly in
trigeminal neurons from female rats nor did the effects of
calcium channel blockers of 5-HT therefore the data from
male and female rats was pooled except where indicated.
In the release experiments 50 mM KCl was used to stimu-
late release of transmitter from cultured cells. Cultures
were incubated for successive 10 minute intervals under
basal and stimulating conditions and after each 10
minute interval, the buffer was exchanged and glutamate
and/or CGRP was assayed. Various subtype-specific cal-
cium channel blockers were added to the release buffer
under non-stimulating (pretreatment) and stimulating
conditions (50 mM KCl). The release obtained in the
absence of a blocker was compared to the release in the
presence of a blocker to determine the contribution of
each of the channel types to CGRP release. As seen in Fig.
1A, exposing trigeminal ganglion neurons from male rats
to 50 mM KCl stimulated glutamate release by more than
ten-fold from a basal level of 58 ± 4 pmol/well/10 min to
602 ± 57 pmol/well/10 min. The addition of 1 µM ω-Aga
TK, a P/Q-type channel blocker [16] decreased the magni-Molecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
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tude of the potassium-stimulated glutamate release by
51% to 297 ± 29 pmol/well/10 min compared to potas-
sium-stimulated glutamate release in the absence of
blocker (p < 0.05), whereas 200 nM ω-Aga TK decreased
the potassium-stimulated release by 37 ± 10% (n = 12, p
< 0.05, data not shown). ω-Cgtx (1 µM), an N-type chan-
nel blocker [17] decreased the magnitude of the potas-
sium-stimulated glutamate release by 58% to 252 ± 32
pmol/well/10 min compared to potassium-stimulated
glutamate release in the absence of blocker (p < 0.05).
Nimodipine (1 µM), an L-type channel blocker [18]
decreased the magnitude of the potassium-stimulated
glutamate release by 63% to 225 ± 16 pmol/well/10 min
compared to potassium-stimulated glutamate release in
the absence of blocker (p < 0.05). None of the three cal-
cium channel blockers reduced the basal release of gluta-
mate. The results of these experiments suggest that P/Q-,
N- and L-type channels each mediate a significant fraction
of depolarization-associated glutamate release from cul-
tured trigeminal neurons.
We also determined the importance of calcium channels
in potassium-stimulated release of CGRP from trigeminal
neurons from male and female rats (Fig. 1B). Potassium
stimulated release of CGRP by over seven-fold from a
basal level of 13 ± 2 fmol/well/10 min to 101 ± 8 fmol/
well/10 min. ω-Aga TK (1 µM) decreased the magnitude
of the potassium-stimulated CGRP release by 61% to 39 ±
4 fmol/well/10 min compared to potassium-stimulated
CGRP release in the absence of blocker (p < 0.05). In addi-
tional experiments, 200 nM ω-Aga TK inhibited potas-
sium-stimulated release of CGRP by 15 ± 4% (n = 12, data
not shown). The addition of ω-Cgtx (1 µM) inhibited
potassium-stimulated CGRP release by 36% to 65 ± 4
fmol/well/10 min compared to potassium-stimulated
CGRP release in the absence of blocker (p < 0.05).
Nimodipine (1 µM) decreased the magnitude of the
potassium-stimulated release of CGRP by 43% to 58 ± 5
fmol/well/10 min compared to potassium-stimulated
CGRP release in the absence of blocker (p < 0.05). None
of the calcium channel blockers reduced the basal release
of CGRP.
Regulation of glutamate and CGRP release by 5-HT 
receptors
We examined the effects of 5-HT on potassium-stimulated
release of glutamate and CGRP. Fig. 2A illustrates the
effects of 10 µM 5-HT on basal and potassium-stimulated
release of glutamate from male rat trigeminal neurons
grown in culture. Exposing trigeminal neurons to 50 mM
KCl increased glutamate release by greater than four-fold
from a basal level of 63 ± 11 pmol/well/10 min to 296 ±
37 pmol/well/10 min. The addition of 10 µM 5-HT signif-
icantly reduced potassium-stimulated release of gluta-
mate by 59% to 120 ± 24 pmol/10 min/well (p < 0.05),
without affecting basal release. Likewise, 1 µM 5-HT sig-
P/Q-, N- and L-type calcium channels contribute to glutamate and CGRP release from trigeminal neurons grown in culture Figure 1
P/Q-, N- and L-type calcium channels contribute to glutamate and CGRP release from trigeminal neurons 
grown in culture. Panels A and B depict glutamate or immunoreactive CGRP in the buffer measured after successive 10 
minute incubations in the absence and presence of 50 mM KCl and/or drugs. Drugs were present as indicated during "Pretreat" 
and "50 mM KCl" incubations but not during the "Basal" incubation. Data is presented as the mean ± S.E.M. and the number of 
wells tested is indicated in parentheses. An asterisk indicates a significant difference (p < 0.05) between the transmitter release 
from control cells and from cells treated with calcium channel blockers. Potassium-stimulated release of glutamate was inhib-
ited by 1 µM ω-Aga TK, 1 µM ω-Cgtx GVIA and 1 µM nimodipine while basal glutamate release was not altered (Panel A). 
Potassium-stimulated release of CGRP was inhibited by 1 µM ω-Aga TK, 1 µM ω-Cgtx GVIA and 1 µM nimodipine while basal 
CGRP release was not altered (Panel B).Molecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
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nificantly reduced the potassium-stimulated release of
glutamate by 35 ± 9% (n = 12, data not shown). Over-
night treatment of the cultures with pertussis toxin (100
ng/ml) abolished the effect of 10 µM 5-HT, indicating the
involvement of Gαi/Gαo signaling. Pertussis toxin did not
affect basal or stimulated release.
As shown in Fig. 2B, 5-HT inhibited release of CGRP from
trigeminal neurons from male and female rats grown in
culture. Potassium stimulated the release of CGRP by
almost twelve-fold from a basal level of 9 ± 1 fmol/well/
10 min to 106 ± 10 fmol/well/10 min. The addition of 10
µM 5-HT reduced potassium-stimulated release of CGRP
Serotonin inhibits release of glutamate and CGRP from trigeminal neurons in a pertussis-toxin sensitive manner Figure 2
Serotonin inhibits release of glutamate and CGRP from trigeminal neurons in a pertussis-toxin sensitive man-
ner. Panels A – C illustrate glutamate or immunoreactive CGRP in the buffer measured after successive 10 minute incubations 
in the absence and presence of 50 mM KCl and/or drugs. Drugs were present as indicated during "Pretreat" and "50 mM KCl" 
incubations but not during the "Basal" incubation. Data is presented as the mean ± S.E.M. and the number of wells tested is 
indicated in parentheses. An asterisk indicates a significant difference (p < 0.05) between the transmitter release from control 
cells and from cells treated with serotonin and/or pertussis toxin. Serotonin (10 µM) inhibits KCl-stimulated but not basal 
release of glutamate (Panel A). Overnight pertussis toxin treatment (100 ng/ml) blocks the serotonergic inhibition of KCl-stim-
ulated glutamate release without affecting basal or KCl-stimulated release. Serotonin (10 µM) inhibits KCl-stimulated but not 
basal release of CGRP (Panel B). Overnight pertussis toxin treatment (100 ng/ml) blocks the serotonergic inhibition of KCl-
stimulated CGRP release without affecting basal or KCl-stimulated release from trigeminal neurons. Serotonin inhibits KCl-
stimulated release of CGRP from trigeminal neurons from female rats in the absence and presence of the calcium channel 
blockers, 1 µM ω-Cgtx GVIA and 1 µM nimodine to a similar extent (Panel C). Serotonin (1 µM) reversibly inhibits calcium 
current amplitude (Panel D). Peak currents were plotted against time for this cell. The trigeminal neurons were depolarized to 
0 mV for 100 msec every 20 seconds from a holding potential of -80 mV. The horizontal bar indicates perfusion of 1 µM 5-HT. 
Inset, superimposed current traces from the indicated time points.Molecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
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by 47% to 56 ± 2 fmol/10 min/well (p < 0.05), without
affecting basal release. Potassium-stimulated release of
CGRP was not significantly decreased by 1 µM 5-HT (13 ±
4% (n = 12), data not shown). Overnight treatment of the
cultures with pertussis toxin (100 ng/ml) blocked the
effect of 10 µM 5-HT without affecting basal or stimulated
release of CGRP.
As we are particularly interested in the P/Q-type channel
we compared the effects of 5-HT on the release of CGRP
from trigeminal cultures from female rats in the presence
and absence of N- and L-type channel activity (Fig. 2C).
When no channel blockers were present potassium stimu-
lated release of CGRP by almost ten-fold from 8.35 ± 0.48
to 75.8 ± 3.13 fmol/well/10 min and 10 µM 5-HT inhib-
ited the stimulated release by 35% (p < 0.05). In the pres-
ence of 1 µM nimodipine and 1 µM ω-Cgtx GVIA, the
stimulated release was 36.4 ± 1.5 fmol/well/10 min (or
48% of the stimulated release in the absence of these two
blockers). The addition of 10 µM 5-HT inhibited the
nimodipine- and ω-Cgtx GVIA-insensitive release by 33%
(p < 0.05).
We hypothesize that 5-HT receptor activation may inhibit
calcium channel function and subsequently reduce
release of neurotransmitters. We have used patch clamp
electrophysiology to characterize the acute effects of 5-HT
on calcium currents in trigeminal neurons [19]. In the
example in Fig. 2D, 1 µM 5-HT reversibly inhibited peak
calcium current amplitude by 31% in a small capsaicin-
sensitive trigeminal neuron, suggesting a mechanism
where 5-HT may reduce release of CGRP.
Sensory neurons express several families of 5-HT receptors
including 5-HT1, 5-HT2 and 5-HT3 [20-23]. Therefore, we
used subtype selective antagonists to determine the roles
of 5-HT1, 5-HT2 and 5-HT3 receptors in controlling neuro-
transmitter release. As depicted in Fig. 3A, 5-HT signifi-
cantly reduced stimulated release of glutamate by 53%
while NAS-181, a 5-HT1B/1D  receptor antagonist [24],
blocked the inhibitory effect of 5-HT without affecting
basal or stimulated release. Likewise, NAS-181 blocked
the ability of 5-HT to inhibit potassium stimulated release
of CGRP (Fig. 3B) without affecting basal or stimulated
release. In contrast, neither SB 200646, a 5-HT2B/2C antag-
onist [25] or Y-25130, a 5-HT3 antagonist [26] was able to
block the inhibitory actions of 5-HT on CGRP release
(Figs. 3C and 3D). In summary, 5-HT inhibits glutamate
and CGRP release from trigeminal cultures by pertussis-
toxin sensitive signaling pathways, probably via 5-HT1
receptors.
Discussion
To our knowledge this is the first assessment of the regu-
lation of glutamate and CGRP release from adult rat
trigeminal ganglion neurons grown in culture. Several
lines of evidence suggest that glutamate is important in
nociceptive signaling in the trigeminal ganglion. NMDA,
kainate, AMPA and metabotropic glutamate receptors are
present in the superficial lamina of the trigeminal nucleus
caudalis in the rat [27]. Also, NMDA and AMPA receptor
antagonists block transmission of trigeminovascular noci-
ceptive signals [28,29] and attenuate the elevated c-fos lev-
els seen in trigeminal nucleus caudalis after intracisternal
capsaicin injection [30]. Our data demonstrate that P/Q-
type channels as well as N- and L-type channels each con-
tribute significantly to glutamate release from cultured
trigeminal cells from male rats in neurotransmitter release
assays. In addition, 5-HT inhibits glutamate release and
this inhibition is blocked by a 5-HT1 receptor antagonist
and is pertussis-toxin sensitive. Our data suggests that 5-
HT receptor signaling regulates the release of glutamate
from trigeminal neurons.
Our data demonstrates that P/Q-type, N- and L-type chan-
nels each contribute significantly to CGRP release from
cultured trigeminal cells from both male and female rats.
While several studies have examined the regulation of
CGRP release from trigeminal neurons by triptans [31],
adenosine [32] and capsaicin [33] none have focused on
identifying which calcium channels are coupled to the
release of CGRP. Some previous studies have determined
that the P/Q-type channel may not be important for
release of CGRP from dorsal root ganglion [34] while oth-
ers suggest that the P/Q-type channel is important in spi-
nal nociceptive processes [35] and particularly in
inflamed tissue [36] in the spinal cord. Our data indicates
that P/Q-, N- and L-type calcium channels are coupled to
release of CGRP from trigeminal neurons. However, it is
unclear at this time whether tissue specific differences
exist in the coupling of calcium channels to neurotrans-
mitter release in trigeminal ganglion and dorsal root gan-
glion.
It has been hypothesized that sumatriptan blocks
migraine pain by attenuating the elevated release of CGRP
from trigeminal nerves. The seminal work of Durham and
Russo [31,37] had previously demonstrated that
sumatriptan can inhibit CGRP promoter activity and stim-
ulated release of CGRP from trigeminal neurons from
neonatal rats. In this study and our previous work [19] we
demonstrate that 5-HT, probably via a 5-HT1 receptor
pathway, inhibits stimulated CGRP release from cultured
adult rat trigeminal neurons. Signaling through 5-HT1
receptors is usually via activation of heterotrimeric G pro-
teins of the Gαi/Gαo class which couple to inhibition of
adenylate cyclase [38]. Our results are consistent with the
involvement of Gαi/Gαo  proteins in 5-HT's signaling
pathway as pertussis toxin abolishes the actions of 5-HT
on release of both neurotransmitters. However, in earlierMolecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
Page 6 of 10
(page number not for citation purposes)
studies in neonatal rat trigeminal neuronsor cell lines
[31,37] sumatriptan increased intracellular calcium rather
than inhibited adenylate cyclase. Pertussis toxin did not
block sumatriptan induced increases in intracellular cal-
cium in CA77 cells, a neuronal-like cell line. In addition,
Carruthers et al., (2001) [32] observed that sumatriptan
did not inhibit forskolin stimulated release of CGRP from
rat trigeminal neurons. At present it is not certain whether
these interesting differences can be attributed to the use of
neonatal versus adult rats, cell lines, different agonists or
other methodological differences. In consideration of
these differences and the clinical importance of the
triptans, additional studies in our adult rat trigeminal cell
cultures with triptans are warranted.
As the prevalence of migraine and other painful disorders
associated with the trigeminal system is higher in females,
we have compared the regulation of neurotransmitter
A 5-HT1 receptor antagonist but not 5HT2 or 5HT3 antagonists block serotonergic inhibition of neurotransmitter release from  trigeminal neurons Figure 3
A 5-HT1 receptor antagonist but not 5HT2 or 5HT3 antagonists block serotonergic inhibition of neurotransmit-
ter release from trigeminal neurons. Panels A-D illustrate glutamate or immunoreactive CGRP in the buffer measured 
after successive 10 minute incubations in the absence and presence of 50 mM KCl and/or drugs. Drugs were present as indi-
cated during "Pretreat" and "50 mM KCl" incubations but not during the "Basal" incubation. Data is presented as the mean ± 
S.E.M. and the number of wells tested is indicated in parentheses. An asterisk indicates a significant difference (p < 0.05) 
between the transmitter release from control cells and from cells treated with serotonin and/or serotonin receptor antago-
nists. NAS-181 (1 µM), a 5-HT1 receptor antagonist, blocks the serotonergic inhibition of release of glutamate and CGRP (Pan-
els A and B, respectively) without affecting basal or stimulated release. SB 200646 (1 µM), a 5-HT2B/2C antagonist does not 
block 5-HT (10 µM) inhibition of KCl-stimulated release of CGRP (Panel C) or alter basal or KCl-stimulated release. Y-25130 
(500 nM), a 5-HT3 antagonist does not block 5-HT (10 µM) inhibition of KCl-stimulated release of CGRP (Panel D) or alter 
basal or KCl-stimulated release.Molecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
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release in trigeminal neurons from male and female rats
grown in culture. Similar to our results in trigeminal neu-
rons from male rats, P/Q-, N- and L-type channels all con-
tribute to release of CGRP in female rats. The effects of 5-
HT on release of CGRP from trigeminal neurons are not
different in male and female rats either. These results sug-
gest that the serotonergic regulation of CGRP release from
trigeminal neurons grown in identical culture conditions
is similar in male and female rats, leading us to pool data
from male and female rats in this report. Notwithstanding
the similarity in regulation of CGRP release we observed
and the difficulties of doing these kinds of comparisons in
isolated cells, previous work indicates that sex differences
are present in signaling in the trigeminal pathway. A com-
pelling body of evidence from Bereiter's group [39-41]
indicates that neurotransmitter release and pain process-
ing differ in male and female rats and during the estrus
cycle in the trigeminal system.
As P/Q-, N- and L-type channels all contribute to neuro-
transmitter release in our assays and all three channel
types are known to be highly regulated by G protein cou-
pled receptors we have compared the effects of 5-HT on
release of CGRP in the absence and presence of N- and L-
type channel blockers (Fig. 2C). Under these conditions
the N- and L-type channel activity will be blocked and
therefore the predominant channels likely to be contrib-
uting to release are the P/Q-type and perhaps R-type chan-
nels, as T-type channels will be inactive during the long
KCl depolarizing stimulus, i.e., T-type currents are maxi-
mally activated at lower voltages and almost completely
inactive in the presence of 50 mM KCL. The effects of 5-
HT in the absence and presence of N- and L-type channel
activity are very similar (35 vs. 33%, respectively), suggest-
ing that the P/Q-type channel may be the primary target
of 5-HT activity. We have also demonstrated that 5-HT
inhibits calcium current amplitude in trigeminal neurons
(Fig 2D and [19]). The data in this report and our previous
studies are in agreement with the hypothesis that seroton-
ergic inhibition of neurotransmitter release in trigeminal
neurons may be due to 5-HT effects on calcium channel
function.
While P/Q-, N- and/or L-type calcium channels are known
to be critical for neurotransmitter release from many cen-
tral and peripheral nerve endings, their role in neurotrans-
mitter release from trigeminal neurons had not been
previously established. In this study, we examined the role
of P/Q-, N- and L-type calcium channels in potassium-
stimulated release of glutamate and CGRP from cultured
trigeminal neurons. Although our data indicates that P/Q-
, N- and L-type channels each mediate a high degree of
neurotransmitter release in cultured trigeminal cells, we
cannot rank the relative importance of each channel type
as the relative contribution of voltage-dependent calcium
channels in neurotransmitter release is dependent on the
conditions used to stimulate release [42]. For example,
the long duration of the depolarizing potassium stimulus
may increase the apparent contribution of the L-type
channel to CGRP release, due to the slow Ca2+-dependent
inactivation of L-type channels compared to the faster
voltage-dependent inactivation exhibited by the P/Q- and
N-type channels (but see Lipscombe et al, 2004 [43]). In
addition, this assay in neurons grown in culture does not
differentiate release from soma and release from termi-
nals. Release of neurotransmitter from the soma of sen-
sory neurons has been described [33,44,45] but the
functional significance is not well-understood. It has been
suggested that somal release from sensory ganglion may
mediate intraganglionic transmission [33,46] and have a
central role in excitability. Somal release of transmitters
such as ATP from neurons within sensory ganglion may
be an important form of communication between neu-
rons and glia [47,48] Our electrophysiology data reveals
that all 3 channel types are localized to the cell soma [19]
and therefore could theoretically mediate neurotransmit-
ter release from the soma of trigeminal ganglion neurons.
Our study which directly assesses the role of calcium
channels in neurotransmitter release from cultured
trigeminal neurons is in agreement with several in vitro
and in vivo studies. For instance, voltage-dependent cal-
cium channels, including P/Q-type calcium channels, are
localized to trigeminal presynaptic nerve terminals in the
dura and the trigeminal nucleus caudalis where they have
a prominent role in trigeminovascular nociception [49-
53]. The P/Q-type calcium channel modulates trigeminal
nociception indirectly through its role in descending pain
pathways such as periaqueductal gray [54] as well. P/Q-
type channels may be involved in initiation of migraine
attacks and/or aura symptoms as well as nociceptive trans-
mission. In addition, release of glutamate in the cortex,
which may trigger cortical spreading depression (some-
times manifest as aura symptoms) and/or migraine pain
by activating the trigeminovascular system, is controlled
predominantly by P/Q-type channels (for review, see
Moskowitz, 2004 [55]). Overall, our data when taken
together with previous studies is consistent with an
important, though not exclusive, role for the P/Q-type
channel in release of neurotransmitters from trigeminal
neurons.
Conclusion
In summary, our data indicates that P/Q-, N- and L-type
calcium channels are important in release of glutamate
and CGRP from trigeminal neurons. In addition, our data
demonstrates that 5-HT, most likely through 5-HT1 recep-
tors, can inhibit release of both neurotransmitters to a
similar degree. To our knowledge this is the first report
demonstrating the regulation of glutamate release fromMolecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
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trigeminal neurons and future studies will allow us to
examine the mechanisms controlling release more thor-
oughly.
Methods
Chemicals
Stock solutions of nimodipine and SB 200646 hydrochlo-
ride (Tocris, Ellisville, MO, USA) were dissolved in
DMSO, diluted daily in release buffer and protected from
light. Stock solutions of ω-Agatoxin TK (Alomone Labora-
tories, Jerusalem, Israel), ω-Conotoxin GVIA (Alomone
Laboratories), 5-HT, NAS-181 (Tocris) and Y-25130
hydrochloride (Tocris) were prepared in H2O and were
diluted daily into release buffer. Pertussis toxin (Calbio-
chem, San Diego, CA, USA) was prepared in H20 and
diluted into F12 growth medium. CGRP peptide was from
Tocris and CGRP antiserum was kindly provided by Dr.
Michael Iadorola (NIH, Bethesda, MD). Other reagents
were obtained from Sigma Chemical Co. (St. Louis, MO)
unless indicated.
Cell culture
All animal procedures were approved by the Animal Care
and Use Committee at the Indiana University School of
Medicine. Trigeminal ganglia neurons were isolated and
grown in culture by a modification of the methods of Eck-
ert et al. (1997) [56]. Briefly, male (100 – 150 g) or age-
matched female Sprague-Dawley rats were rendered
unconscious with carbon dioxide before cervical disloca-
tion. For each experiment, trigeminal ganglia from 4–9
male female rats were dissected from the bony base of the
brain, rinsed in ice-cold Puck's saline (Ca2+ free, Mg2+ free)
and minced. All tissue was pooled and single cells were
isolated by sequential exposure to Puck's saline contain-
ing papain (20 units/ml, Worthington, Lakewood, NJ,
USA) followed by collagenase (0.1%) and dispase
(0.25%, Roche, Indianapolis, IN, USA) for 18–20 minutes
each. After washing, cells were resuspended in F12
medium (Gibco, Carlsbad, CA, USA) containing 10%
fetal calf serum (Gibco), 2 mM glutamine, 100 ug/ml pen-
icillin and streptomycin and 30 ng/ml NGF (Harlan Bio-
products, Indianapolis, IN, USA) and maintained at 37°C
and 5% CO2. The contribution of non-neuronal cells was
reduced by adding 50 µM 5-fluoro-2'-deoxyuridine and
150 µM uridine to the media. Cells were plated onto 12
well plates coated with polylysine and laminin. The F12
growth medium was changed every second day and the
cells were used for release studies 7 – 10 days after plating.
Electrophysiology studies
Trigeminal neurons were isolated as described above and
plated on glass coverslips coated with polylysine and lam-
inin. Whole cell patch clamp recordings were conducted
1–2 days after plating. Gigaohm seals were obtained and
calcium currents were measured in TEA/Ba based extracel-
lular recording solution and electrode resistance was 0.8 –
1.5 MΩ when filled with a CsCl-based internal solution
[57]. Membrane currents were recorded on a computer
using PCLAMP software (Axon Instruments, Union City,
CA). Ionic currents were elicited by step depolarizations
of 100 ms duration to a test potential of 0 mV from a
holding potential of -80 mV every 20 seconds. Leak and
capacitive currents were subtracted on-line with a P/4 pro-
tocol. Series resistance was compensated up to 70–80%.
Capsaicin sensitivity was tested after calcium current
recording by perfusing 1 µM capsaicin at a holding poten-
tial of -70 mV.
Release studies
Briefly, the protocol for release studies is as follows [58].
All solutions and cells were maintained at 37°C during
the release experiments. Prior to the release experiment,
cells were washed three times with HEPES buffer contain-
ing 25 mM HEPES, 140 mM NaCl, 3.5 mM KCl, 2.5 mM
CaCl2, 1 mM MgCl2, 3.3 mM D-glucose, and 1% bovine
serum albumin (pH 7.4). The cells were then incubated
with HEPES buffer at 37°C for 1 h followed by three more
washes. Cells were then exposed to successive 10 minute
incubations in the absence or presence of drugs to assay
release. For example, basal or resting immunoreactive
CGRP release was measured in all wells after 10 minute
incubations in 400 or 500 ul HEPES buffer alone (basal).
Then, the HEPES buffer was removed, saved for assay and
replaced with HEPES buffer alone or HEPES buffer con-
taining calcium channel blockers or serotonergic drugs
(pretreatment). Likewise, 10 minute incubations with the
addition of 50 mM KCl to the HEPES buffer were utilized
to evoke neurotransmitter release in the presence or
absence of drugs. After stimulation the cells were exposed
to HEPES buffer alone again to re-establish basal release.
The supernatants were collected following each 10 minute
interval for CGRP radioimmunoassay and/or glutamate
assay. Each drug and diluent utilized (calcium channel
blockers, serotonergic drugs, pertussis toxin) was tested to
determine that it did not interfere with either the CGRP or
glutamate assay by adding the indicated concentrations to
replicate points in the standard curve. For example, the
final concentration of DMSO used in some experiments
was 0.01% or less and did not alter basal or stimulated
release of CGRP or glutamate or CGRP or glutamate assays
(data not shown).
CGRP radioimmunoassay
Total immunoreactive CGRP released into the buffer was
determined by radioimmunoassay as previously
described [58]. Briefly, 25 µl of CGRP antibody
(1:130,000 dilution) and 25 µl of [125I] [Tyr0] CGRP (28–
37) containing 4000–6000 cpm were added to each sam-
ple and to the standards. The samples were incubated with
radiolabeled peptide and antiserum for 16 – 20 h at 4°C.Molecular Pain 2008, 4:12 http://www.molecularpain.com/content/4/1/12
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Tracer not bound to antibody was removed from tracer
bound to antibody by adding 0.5 mL of a 0.1 M phos-
phate buffer (pH 7.4) containing 1% Norite charcoal, 50
mM NaCl, and 0.1% bovine serum albumin. This mixture
was centrifuged at 1000 × G for 20 min at 4°C, the super-
natant was decanted, and the radioactivity was measured
by gamma scintillation spectrometry. The amount of
CGRP in unknown samples was estimated by comparing
the percent bound radioactivity in unknowns to a stand-
ard curve using a four-point nonlinear least squares
regression analysis. Using this method, the minimal
detectable amount of CGRP was 0.5 fmol.
Glutamate assays
Glutamate was measured by HPLC separation and electro-
chemical detection of the OPA-mercaptoethanol deriva-
tive using modifications of the methods of Donzanti &
Yamamoto [59,60]. Using this method, the minimal
detectable amount of glutamate was 2.5 pmol.
Statistical analysis
Each experiment was completed at least three times with
independent trigeminal preparations. In some experi-
ments, we assayed both glutamate and CGRP from the
same wells. Data from individual experiments were
pooled for graphical presentation and further statistical
analysis with GraphPad software (San Diego, CA). Inhibi-
tion of CGRP or glutamate release was calculated by com-
paring the release evoked by potassium in the presence of
drug to the release evoked by potassium in the absence of
drug and displayed as a percent for each experiment and
averaged across experiments. Data are presented as mean
± S.E.M. Repeated measures ANOVA was used to compare
groups and where appropriate posthoc Bonferroni tests
were performed. The significance level for all tests was set
at p < 0.05.
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